W2G BIOPHARMA

Unlocking BIoTheraputics

W2G Latest News:

Micropropagation.png

Advancing Medical Therapy & Innovation

W2G

  • 1 in 4 will suffer from Mental Illness

  • 1 in 5 will suffer from Depression

  • 1 in 5 will suffer from Addiction

It’s Time To Change The Way We Look At Medicine…

Medical Thinking Redesigned

ammo%252520flower_edited_edited_edited.p
Organic Production

HIGHLIGHTS

 

Psilocybin Dealer License Confirmed For Nov 8, 2021

Cannabis License Received Nov 2020

Cannabis Operations Commence Jan 2021

Over 35 New Genetic Cannabis Strains

 

Cannabis Sales Begin April 2021

Cannabis + Psilocybin Cultivation

We believe wellness starts with a standardized organic growth plan. By combining our expertise in organic cultivation technology, proprietary genetics and our experienced OKO Genetic team, Way2Grow Biopharma is able to grow the highest quality, terpene rich, consistent organic medical cannabis.

Tissue Culture Lab

We customize medical grade organic strains in a completely sterile production environment while reducing disease, pests, and pathogens. Our small batch approach focuses on cultivar specific  environments to apply a refining, stabilizing, and purifying methodology to customize cultivars for specific medical needs.

 

Screen%20Shot%202021-04-20%20at%201_edit

Micropropagation

HIGHLIGHTS

Cannabis License received Nov/2020

Cannabis Tissue culture Lab operational Feb 2021

 

Pre-Orders start Feb 2021

 

Genetic Leasing & Sales Begin April/May 2021

Psilocybin Tissue Culture anticipated

November 8,  2021

mushrooms1.jpg

Cannabis + Psilocybin Extraction

W2G received a Standard Cannabis Cultivation License toward the end of 2020.   At W2G we focus on isolating the THC, CBD, Terpenes and Cannabinoids from the cannabis flower to give our medical patients the richest organic medical extracts available.

 

 Science & Innovation

 It is believed that some psychedelics such as psilocybin mushrooms, may help re-focus old behaviour patterns and build new and healthier ones as seen from the creation of new neural pathways.  By standardizing growth plans and extraction techniques, we are developing more consistent standards used in the production and extraction of psilocybin mushrooms for medical use.

 

Psilocybin Application (Submitted) January 2020

 

Section 56  Research Exemption Submission (Pending)

 

Research Laboratory Summer 2021

 

Psilocybin License Pending - November 8, 2021

Research Laboratory

HIGHLIGHTS

 

Medical Sales + Global Distribution

Medical Sales License & EU-GMP Facilities allow for import/export product to/from other medically licensed facilities internationally.

W2G Biopharma has a specialized team to draw up the import and export license paperwork to ensure we meet compliance and regulatory framework to import and export our W2G organic products.

W2G is developing strong strategic global partnerships to promote safe and responsible production and distribution of cannabis products.